FDA documents show struggle over approval of new Alzheimer’s drug from Biogen
Published
Published
INDIANAPOLIS (AP) — Eli Lilly is nearly ready to take another shot at getting approval for a possible Alzheimer's..
The F.D.A.'s approval of the Alzheimer's drug aducanumab is inexplicable.